Addex Pharmaceuticals (ADDXF.PK) announced the extension of its research collaboration with Merck & Co., Inc. (MRK), through an affiliate, for an additional year. The collaboration is focused on developing positive allosteric modulators of the metabotropic glutamate receptor 4 for the treatment of Parkinson's disease and other undisclosed indications.
Addex will receive research funding from Merck in addition to the original financial terms, which include milestones and royalties.
For comments and feedback: editorial@rttnews.com